Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1/PHASE2
2121 participants
INTERVENTIONAL
2023-07-31
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating an Ebola and a Marburg Vaccine in Uganda
NCT00997607
Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
NCT02564523
Phase 1 Trial of Ebola Vaccine in Mali
NCT02267109
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
NCT05762393
Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults
NCT03420053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is an urgent need to test the safety and immunogenicity of the candidate vaccine(s) developed against Sudan ebolavirus. Once safety and immunogenicity (including extended immunogenicity) have been proven, these vaccines could be deployed for future outbreaks as part of the response.
OBJECTIVES Phase 1 Objectives
1. To determine the safety of rVSV-SUDV candidate SUDV vaccine among healthy volunteers
2. To determine the immunogenicity of rVSV-SUDV candidate SUDV vaccine
Phase 2 Primary objectives
1. To determine the safety of ChAdox1, CAd3 and rVSV-SUDV candidate SUDV vaccine(s) among healthy volunteers and persons with stable comorbidities.
2. To determine the immunogenicity of the three candidate SUDV vaccines.
Secondary objectives
1. To determine the durability of SUDV-specific induced immune responses following vaccination with ChAdox1, CAd3 and rVSV-SUDV candidate SUDV vaccine(s).
2. To determine the factors associated with vaccine-induced immune responses.
3. To determine the putative cross reactivity \& protection exerted by the SUDV vaccine candidates against other ebolaviruses (e. g. Bundibugyo ebolavirus (BUDV) and EBOV).
Exploratory objectives
1. To determine the effect of SUDV vaccines on host gene expression
2. To determine the T and B cell specific responses and immune profiling in response to vaccination
3. To determine the effect of SUDV vaccines on the host metabolome
4. To determine the effect of SUDV vaccines on host immune responses
END POINTS
Primary Endpoints
1. Number of solicited, unsolicited adverse and serious adverse events that are determined as possibly, probably and definitely related to the investigational products.
2. Binding antibody titres, neutralization activity and cell mediated immune responses.
Secondary Endpoints
1. Durability of SUDV-specific induced immune responses following vaccination.
2. Factors associated with vaccine-induced immune responses.
3. To determine the putative cross reactivity \& protection exerted by the SUDV vaccine candidates against other ebolaviruses (e. g. Bundibugyo ebolavirus (BUDV) and EBOV).
TRIAL PARTICIPANTS This trial will enroll a total 250 healthy, adult volunteers (18-50 years) (150 intervention arm and 100 placebo arm) for the phase I rVSV-SUDV vaccine. The DSMB will review day 28 post vaccination safety data for all the phase I participants and day 56 post vaccination binding antibody IgG and IgM data for 50 participants randomly selected who receive the rVSV SUDV and 10 participants who receive the placebo to make a recommendation regarding proceeding to phase II. Participants enrolled in phase I of the rVSV-SUDV candidate vaccine will contribute data to phase II for this vaccine. For the Phase II trial (ChAdox1, CAd3 and rVSV-SUDV vaccines), 2121 volunteers aged 6 - 65 years will be included (606 for each of the vaccine arms and 303 to placebo). A randomly selected subset of120 participants per vaccine and 50 placebo recipients will participate in extended immunogenicity studies (long term immunogenicity and exploratory studies). 100 participants from each intervention arm participating in extended immunogenicity will randomly be selected to receive a homologous booster 12months post vaccination.
STATISTICAL ANALYSIS The primary analysis is the comparison of occurrence of solicited (within 7 days) and unsolicited adverse events (occurring within 56 days) considered possibly, probably or definitely related to vaccines as well as adverse and SAEs occurring within 24 months' post-vaccination between each candidate vaccine and placebo. AEs will be summarized with counts, percentages, and, when provided, exact 95% CIs will be provided. SAEs will be graded according to DAIDS. The primary analysis for the immunogenicity is the change in serum IgG and IgM titres from baseline to 56days post vaccination.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Candidate vaccine 1
One injection of cAd3 will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
CAd3
CAd3 candidate vaccine which is one of the investigational products
Candidate vaccine 2
One injection of chAdOx1 will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
ChAdox1
ChAdox1 candidate vaccine which is one of the investigational products
Candidate vaccine 3
One injection of rVSV-SUDV will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
rVSV-SUDV
rVSV-SUDV candidate vaccine which is one of the investigational products
Control
One injection of placebo will be administered to the study participants at enrollment. The participants will be monitored for 30 minutes after receipt of the vaccine and thereafter follow up done at different time points up to 72 months.
Control
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Control
Placebo
CAd3
CAd3 candidate vaccine which is one of the investigational products
ChAdox1
ChAdox1 candidate vaccine which is one of the investigational products
rVSV-SUDV
rVSV-SUDV candidate vaccine which is one of the investigational products
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy volunteers aged 18-50 years from study communities
* Healthy volunteers with a permanent home address
* Able and willing to complete and provide written informed consent. In case the participant cannot read or write, the procedures must be explained to him/her and informed consent must be witnessed by a literate third party not involved with the conduct of the study
* Participant must pass the informed consent test of understanding (TOU)
* Participant must be healthy in the investigator's clinical judgement on the basis of medical history, physical examination, vital signs and point of care tests (where applicable) performed at screening
* If female of child-bearing potential and heterosexually active, practice of adequate contraception for 28 days prior to injection, negative pregnancy test on the day of vaccination, and agreement to continue adequate contraception until 90 days after vaccination
* Male participants are eligible to participate in the study if they agree to use a male condom during any heterosexual intercourse with a female of childbearing potential until 90 days after vaccination
Phase 2
* Healthy volunteers aged 6 years-65 years from study communities. Individuals with comorbidities assessed as stable will be allowed to participate
* With a permanent home address
* Able and willing to complete and provide written informed consent or assent as applicable. In case the participant cannot read or write, the procedures must be explained to him/her, and informed consent must be witnessed by a literate third party not involved with the conduct of the study.
* Participant must pass the informed consent or assent test of understanding (TOU)
* Participant must be healthy according to the investigator's clinical judgement on the basis of medical history, physical examination, vital signs and point of care tests (where applicable) performed at screening
* If female of child-bearing potential and heterosexually active, practice of adequate contraception for 28 days prior to injection, negative pregnancy test on the day of vaccination, and agreement to continue adequate contraception until 180 days after vaccination
* Male participants are eligible to participate in the study if they agree to abstain from any heterosexual intercourse with a female of childbearing potential or must agree to use a male condom
Exclusion Criteria
* History of confirmed ebola virus diseases (SUDV, EBOV or BUDV)
* Unwillingness of female participants to use effective contraception
* Participation in an interventional clinical trial within 90 days of participation in this trial
* Prior vaccination with any Ebola vaccine
* Breastfeeding or planning to conceive within 2 months following study vaccination
* Has history of fever (\>100.4ºF/38.0ºC) within 48 hours prior to enrolment into the study
* Received systemic corticosteroids exceeding physiologic replacement doses (\~5 mg/d prednisone equivalent) within 14 days prior to study entry
* Received any live virus vaccine within 30 days or any non-live virus vaccine within 14 days prior to study entry
* Has a known allergy/sensitivity or contraindication to investigational vaccines or its/their excipients?
* History of malignancy ≤5 years
* Major surgery within the 4 weeks prior to screening or planned major surgery through the course of the study (from screening until completion of the study)
* Presence of any condition that can interfere with the subject's participation for the full duration of the trial.
* HIV positive
* Hepatitis B positive
Phase 2
* History of confirmed SUDV
* Unwillingness of female participants to use effective contraception
* Participation in an interventional clinical trial within 90 days of start of this trial
* Prior vaccination with any Ebola vaccine
* Breastfeeding or planning to conceive within 2 months following study vaccination
* Has history of fever (\>100.4ºF/38.0ºC) within 48 hours prior to vaccination
* Received systemic corticosteroids exceeding physiologic replacement doses (\~20 mg/d prednisone or equivalent) for 14 days within a month prior to study entry.
* Immunosuppressive medication within 3 months
* Received any live virus vaccine within 30 days or any non-live virus vaccine within 14 days prior to study entry
* Has a known allergy/sensitivity or contraindication to investigational vaccines or its/their excipients?
* History of malignancy ≤5 years
* Major surgery within the 4 weeks prior to screening or planned major surgery through the course of the study (from screening until completion of the study)
* Presence of any condition that can interfere with the subject's participation for the full duration of the trial
6 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Makerere University Lung Institute
UNKNOWN
MRC/UVRI and LSHTM Uganda Research Unit
OTHER
Makerere University Walter Reed Program
UNKNOWN
Epicentre
OTHER
Uganda Virus Research Institute-International Aids Vaccine Initiative
UNKNOWN
Ministry of Health, Uganda
OTHER_GOV
Makerere University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bruce J Kirenga
Prof
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TOKOMEZA PLUS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.